Brukinsa
FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for ...
MARCH 8, 2024
Brukinsa Granted Accelerated Approval for Treatment of R/R MZL
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adults with relapsed or refractory ...
OCTOBER 13, 2021
Load more